Gemcitabine-Docetaxel May Be a Feasible Alternative to BCG for High-Risk NMIBC

Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. Intravesical sequential gemcitabine-docetaxel may be a feasible alternative to BCG for high-risk nonmuscle-invasive bladder cancer (NMIBC).

Related Keywords

Wake Forest University ,North Carolina ,United States ,Winston Salem ,Washington ,Vignesht Packiam ,Justin Manuel Refugia ,Society Of Urologic Oncology ,Wake Forest University School Of Medicine ,University Of Iowa ,Urologic Oncology ,Wake Forest University School ,Cancers Symposium ,Iowa City ,